Xin Lang Cai Jing·2026-03-27 06:53Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, and a cumulative increase of 6.82% over three consecutive days [1][6]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][6]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][6][7]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [7]. Shareholder Insights - Huatai-PB Fund's Huatai-PB CSI 300 ETF (510300) has entered the top ten circulating shareholders of Tiger Med, holding 8.78 million shares, which is 1.27% of the circulating shares. The estimated floating profit today is approximately 22.30 million CNY, with a total floating profit of 28.44 million CNY over the three-day increase [2][8]. - The Huatai-PB CSI 300 ETF was established on May 4, 2012, with a current scale of 422.26 billion CNY. Year-to-date, it has experienced a loss of 3.16%, ranking 3698 out of 5563 in its category, while it has gained 17.24% over the past year, ranking 2622 out of 4429 [2][8]. Fund Performance - The fund manager of Huatai-PB CSI 300 ETF is Liu Jun, who has a tenure of 16 years and 301 days, managing assets totaling 550.93 billion CNY. The best fund return during his tenure is 205.53%, while the worst is -45.64% [3][8]. - Huatai-PB Medical Health A (005805) has increased its holdings in Tiger Med by 5,950 shares, totaling 273,500 shares, which represents 5.02% of the fund's net value, making it the fourth-largest holding. The estimated floating profit today is about 694,700 CNY, with a total floating profit of 886,100 CNY over the three-day increase [4][9]. - The Huatai-PB Medical Health A fund was established on June 25, 2018, with a current scale of 251 million CNY. It has incurred a loss of 5.46% year-to-date, ranking 7497 out of 8898, while gaining 4.27% over the past year, ranking 6365 out of 8181 [4][9]. Fund Manager Insights - The fund manager of Huatai-PB Medical Health A is Zhang Hong, who has a tenure of 6 years and 145 days, managing assets totaling 2.21 billion CNY. The best fund return during his tenure is 105.24%, while the worst is -19.01% [5][10].